Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test
Abstract
The Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test, v2.0 (the CAP/CTM assay), was used to quantify cell-associated HIV-1 (CAH) nucleic acid in peripheral blood mononuclear cells (PBMC) from well-characterized clinical specimens from HIV-1-infected individuals on antiretroviral therapy (ART). Chronically infected individuals on ART with no detectable plasma HIV-1 RNA demonstrated average CAH burdens of 3.2 HIV-1 log 10 copies/million cells.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 01, 2019
- Source ID
- 10.1128/jcm.01922-18
Entities
People
- Donn J. Colby
- Eugène Kroon
- Holly R. Hack
- Jennifer A. Malia
- Jintanat Ananworanich
- Joanna Freeman
- Linda L. Jagodzinski
- Mark M. Manak
- Mark de Souza
- Michelle A. Lally
- Nelson Michael
- Nitiya Chomchey
- Nittaya Phanuphak
- Sheila A. Peel
- Ying Liu
Organizations
- Brown University
- National Institutes of Health
- Thai Red Cross Society
- U.S. Military HIV Research Program
- United States Army Medical Research and Development Command
- Walter Reed Army Institute of Research